According to regulatory filings released Friday, preliminary revenue climbed 35.2 percent to 1.3 trillion won, with the operating margin widening to about 33 percent from 25 percent a year earlier as newer, higher-margin products gained ground.
Newer products, including Zymfentra, Yuflyma and Steqeyma, now account for more than 60 percent of total sales, the company said, with Zymfentra setting fresh prescription records in the United States and Steqeyma climbing into the market's leading tier.
In Europe, Omlyclo has maintained its first-mover advantage, while Vegzelma has held the top market share in several countries despite entering later than rivals, according to the filing.
Celltrion is also expanding production capacity, adding 180,000 liters of capacity in South Korea and 75,000 liters at its New Jersey plant, which will lift its total U.S. output capacity to 141,000 liters.
"This result shows that our strategy of expanding new products and improving profitability is beginning to bear fruit," said a Celltrion spokesperson, adding the company expects momentum to build further in the second half.
Copyright ⓒ Aju Press All rights reserved.